{"Clinical Trial ID": "NCT00006110", "Intervention": ["INTERVENTION 1:", "- Herceptin diet after AC", "Patients in adjuvant and neoadjuvant groups after receiving [AC-TP] chemotherapy (doxorubicin and cyclophosphamide).", "INTERVENTION 2:", "- Herceptin diet after TP", "Patients in adjuvant and neoadjuvant groups after receiving chemotherapy and Taxol + Herceptin."], "Eligibility": ["\u2022 Inclusion criteria", "In histological order, the previously untreated Stage IIB, IIIA, IIIB, IIIC or Stage IV primary carcinoma of the breast is confirmed.", "\u2022 Fine needle aspiration, central needle biopsy or authorized incisional biopsy", "No excision biopsy", "Any of the following situations:", "- Tumors of size 2, knots 1 (T2N1) or tumours of size 3 knots 0 (T3N0)", "Any T with N2 (including axillary lymph nodes coupled to each other) or N3", "All T4, including inflammatory breast cancer", "\u2022 Adjuvant patients with at least 4 positive lymph nodes and an overexpressive HER-2 tumour", "\u00b7 Positive supraclavicular or infraclavicular lymph nodes without distant metastases", "Remote metastases with measurable disease in breast or lymph nodes", "If the most serious cancer meets the entry criteria, synchronous bilateral primary breast cancer is allowed.", "A measurable or evaluable disease", "CHARACTERISTICS OF PATIENTS:", "Age: Not specified", "Gender: Female", "Status of menopause: Unspecified", "State of execution: Unspecified", "Life expectancy: Not specified", "Haematopoietic:", "Number of white cells > 3000 / mm3 Number of platelets > 100,000 / mm3", "Haemoglobin > 9 mg/dl Bilirubin < 1.5 x normal Creatinine < 1.5 x normal left ventricular ejection fraction (VEF) normal by resting nuclear ventricularogram No pregnancy or breast-feeding Negative pregnancy test Fertile patients should use effective contraception", "- Exclusions", "With the exception of previous malignancies:", "In situ carcinoma of the cervix that has been treated curatively by surgery alone Non-mammary disease whose patient has been disease-free for 5 years and has a low risk of recurrence"], "Results": ["Performance measures:", "When delivered immediately after four standard AC dose cycles, weekly herceptin is administered as a cardiac toxicity of the weekly taxol.", "Doxorubicin + cyclophosphamide in combination with paclitaxel and trastuzumab (AC-TP) Associated systolic function. Systolic function was measured by ventricular ejection fraction (LVEF).", "Time limit: 78 weeks (1.5 years)", "Results 1:", "Title of the arm/group: Herceptin diet after AC", "Description of the arm/group: Patients in adjuvant and neoadjuvant groups after receiving [AC-TP] chemotherapy (doxorubicin and cyclophosphamide).", "Total number of participants analysed: 52", "Type of measure: Number of participants", "Unit of measure: asymptomatic FEVA participants < 50 %: 1,9 %", "Congestive heart failure: 0 0.0%", "Results 2:", "- Arm/group title: Herceptin diet after TP", "Description of the arm/group: Patients in adjuvant and neoadjuvant groups after receiving chemotherapy and Taxol + Herceptin.", "Total number of participants analysed: 50", "Type of measure: Number of participants", "Unit of measure: Asymptomatic FEVA participants < 50%: 8 16.0%", "Congestive heart failure: 1 2.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/52 (13.46 per cent)", "\u2022 Neutropenia febrile (fever of unknown origin without clinically or microbiologically documented infuse * 0/52 (0.00 %)", "Atrial fibrillation * 1/52 (1.92%)", "\u2022 Sepsis * 1/52 (1.92%)", "Upper limb muscle weakness * 1/52 (1.92%)", "* 1/52 (1.92%)", "Seizure * 1/52 (1.92%)", "- Nervous system disorders - Other, specify * [1]1/52 (1.92%)", "Adverse Events 2:", "Total: 1/30 (3.33%)", "Fever of unknown origin without clinically or microbiologically documented infuse * 1/30 (3.33%)", "Atrial fibrillation * 0/30 (0.00 %)", "Sepsis * 0/30 (0.00 %)", "Upper limb muscle weakness * 0/30 (0.00 %)", "* 0/30 (0.00 %)", "\u2022 Seizure * 0/30 (0.00 %)", "- Nervous system disorders - Other, specify * [1]0/30 (0.00 %)"]}